Safety and efficacy of immunotherapy according to the age threshold of 80 years-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of immunotherapy according to the age threshold of 80 years

Published:2023-05 Issue:5 Volume:110 Page:570-580
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:en
Short-container-title:Bulletin du Cancer

Author:

Mebarki Soraya,Pamoukdjian Frédéric,Pierro Monica,Poisson Johanne,Baldini Capucine,Widad Lahlou ,Taieb Julien,Fabre Elizabeth,Canoui-Poitrine Florence,Oudard Stéphane,Paillaud Elena

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference25 articles.

1. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis;Duan;JAMA Oncol,2020

2. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis;Wang;J Cell Physiol,2020

3. Immune therapies for myelodysplastic syndromes and acute myeloid leukemia;Kapoor;Cancers,2021

4. Global cancer incidence in older adults, 2012 and 2035: a population-based study;Pilleron;Int J Cancer,2019

5. Inclusion of older patients with cancer in clinical trials: the SAGE Prospective Multicenter Cohort Survey;Canouï-Poitrine;The Oncologist,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP